Erythropoiesis-stimulating agents (ESAs) are the main treatment for CKD patients with anaemia [2] and are effective in correcting and maintaining haemoglobin (Hb) levels and decreasing the need for blood transfusions. This evidence concerns the gene GSTM1 and anemia.